Orion

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

30 January 2025 — Espoo, Finland — Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform. Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform…

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Darolutamide plus ADT now has positive data both with and without docetaxel based on two pivotal Phase III…

Orion and Bayer expand clinical development program for darolutamide in prostate cancer

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage.

Orion and Amneal enter strategic partnership ‚Ä’ Orion receives exclusive licence to commercialise Amneal‚Ä™s generic products in Europe, Australia and New Zealand

Orion Corporation today announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amnealís generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialise and sell Amnealís generic products in most parts of Europe as well as in Australia and New Zealand. The…